UC Office of the President

Recent Work

Title

Expression of epigenetic modifiers is not significantly altered by exposure to secondhand smoke.

Permalink

<https://escholarship.org/uc/item/0rr0r699>

Journal

Lung cancer (Amsterdam, Netherlands), 90(3)

ISSN

0169-5002

Authors

Tommasi, Stella
Zheng, Albert
Besaratinia, Ahmad

Publication Date

2015-12-01

DOI

10.1016/j.lungcan.2015.10.023

Peer reviewed

Contents lists available at ScienceDirect

Lung Cancer

journal homepage: www.elsevier.com/locate/lungcan

Expression of epigenetic modifiers is not significantly altered by exposure to secondhand smoke

Stella Tommasi*, Albert Zheng, Ahmad Besaratinia

Department of Preventive Medicine, USC Keck School of Medicine, University of Southern California, M/C 9603, Los Angeles, CA 90033, USA

ARTICLE INFO

Article history:

Received 18 August 2015
Received in revised form 20 October 2015
Accepted 22 October 2015

Keywords:

DNA methyltransferases (DNMTs)
Epigenome
Histone deacetylases (HDACs)
Lung cancer
Methyl-CpG binding domain proteins (MBDs)
Nonsmokers

ABSTRACT

Objectives: Secondhand smoke (SHS) is a major risk factor for lung cancer in nonsmokers. DNA damage-derived mutagenicity is a well-established mechanism of SHS-carcinogenicity; however very little is known about the impact of SHS exposure on the epigenome.

Materials and methods: We have investigated whether exposure to SHS can modulate the expression of key epigenetic regulators responsible for the establishment and/or maintenance of DNA methylation and histone modification patterns *in vivo*. We have sub-chronically exposed mice to a mutagenic but non-tumorigenic dose of SHS, and subsequently determined the expression levels of major epigenetic modifiers in the lungs of SHS-exposed mice, immediately after termination of exposure and following 7-month recovery in clean air.

Results and conclusion: Quantification of the expression of genes encoding DNA methyltransferases (*Dnmt1*, *Dnmt3a*, *Dnmt3b* and *Dnmt3l*), methyl binding domain proteins (*Mecp2*, *Mbd2* and *Mbd3*) and histone deacetylases (*Hdac1* and *Hdac2*) by quantitative reverse-transcription polymerase chain reaction analysis showed modest but not statistically significant differences in the relative transcription of these key epigenetic regulators between SHS-exposed mice and age-matched controls. The non-significant changes in the expression of main epigenetic modifiers in SHS-exposed mice imply that SHS may predominantly induce genotoxic effects, particularly at non-tumorigenic doses, whereas epigenetic effects may only be secondary and manifest *en route* to tumor formation.

© 2015 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Secondhand smoke (SHS), also known as passive smoke, involuntary smoke, or environmental tobacco smoke, is a significant public health concern, and a major risk factor for lung cancer and other diseases [1–4]. Recent estimates show that in 2004, SHS has caused a total of 603,000 deaths, equivalent to 1.0% of all deaths worldwide [3]. In the United States alone, about 10,000–15,000 never smokers die annually from lung cancer [5]. One third of these deaths are ascribed to exposure to SHS [5]. Despite the extensive epidemiologic data supporting the link between SHS exposure and lung cancer, the underlying molecular mechanisms remain largely unknown [2,4,6,7]. A better understanding of the mechanism(s) of action of SHS in the genesis and development of lung cancer in non-smokers can help devise future strategies for prevention, early detection, treatment and prognosis of this malignancy [6–8].

Recent work in our laboratory has established a genotoxic mode of action for SHS based on the ability of this carcinogen to induce DNA damage and mutation that may lead to deregulation of cancer-related genes [9–12]. Most recently, we have also identified epigenetic modulation of gene expression as an alternative mechanism of chemical carcinogenesis *in vivo* [11]. Whether SHS can impact the epigenetic machinery in the lungs of nonsmokers, however, remains to be determined [7,13]. Investigating the epigenetic regulation of gene expression by SHS is paramount to the identification of potential targets of cancer therapy because epigenetic alterations are reversible through pharmacologic interventions and/or genetic manipulations [14–17].

Genetic defects in the epigenetic enzymes, including those involved in the DNA methylation and histone modification pathways, are frequently found in human cancer [18–21]. Though DNA methylation and histone modifications require different sets of enzymes and chemical reactions for mark deposition, the two systems are known to mutually regulate each other during mammalian development and cancer [22–24]. In mammals, methylation at the 5-position of cytosine is catalyzed by DNA methyltransferases (DNMTs) [25,26]. DNMT1 is the most abundant methyltransferase;

* Corresponding author. Fax: +1 323 865 0103.

E-mail address: tommasi@med.usc.edu (S. Tommasi).

it binds preferentially to hemimethylated DNA and is involved in the maintenance of DNA methylation patterns in the daughter strands during DNA replication [27]. DNMT3A and DNMT3B related proteins bind mostly to unmethylated CpG dinucleotides and are responsible for *de novo* methylation during development [25,26]. Though lacking catalytic activity itself, DNMT3L enhances the binding activities of the *de novo* methyltransferases [28]. Expression levels of DNMTs, in particular those of DNMT1, DNMT3A, and DNMT3B, have been shown to be elevated in various types of human cancer, including lung cancer [20,26].

Methyl-CpG binding domain (MBD) proteins are a prominent class of epigenetic enzymes that play a crucial role in the transcriptional state of the epigenome [29]. MBD proteins bind to methylated DNA and coordinate the cross-talk between DNA methylation, histone modifications, and chromatin organization [30]. Disrupted gene expression of MBDs can affect the level of DNA methylation and has been detected in different types of human cancer, cancer cell lines and various mouse models of human cancer [30]. Another important family of epigenetic modifiers is histone deacetylases (HDACs) [31]. HDACs are known to play a key role in several physiological and pathological states, including cancer [32]. HDACs are recruited to chromatin remodeling complexes via the MBD proteins [33] and catalyze the removal of acetyl groups from lysine residues on histone tails, leading to chromatin condensation and gene transcriptional repression [31,32]. To date, several classes of HDACs have been identified [31,34]. Aberrant expression of Class I subfamily of HDACs (*i.e.*, HDAC1 and HDAC2) has been observed in a variety of human cancers, including lung cancer, and is often associated with higher stage and poor prognosis [31,34–36].

Accumulating evidence shows that genetic mutations in epigenetic regulators are associated with an altered epigenome in human cancer [18–21]. The re-shaping of the epigenome in human cancer has also been attributed to exposure to a variety of mutagens and carcinogens [37,38]. To determine whether epigenetic aberrancies in human cancer are indeed caused by exposure to mutagenic compounds, we have used the example of SHS-carcinogenicity and investigated whether exposure to SHS can influence the expression of key epigenetic modifiers *in vivo*. To this end, we have sub-chronically exposed mice, whole body, to SHS in exposure chambers of a microprocessor-controlled smoking machine, and subsequently determined the expression levels of major epigenetic regulators in the lungs of SHS-exposed mice. Total RNA was extracted from the lungs of SHS-exposed mice, immediately after discontinuation of exposure and following 7-month recovery in clean air to establish the short-term and long-term effects, respectively, of SHS. We have used standard quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis to examine changes in the expression of genes encoding DNA methyltransferases (*Dnmt1*, *Dnmt3a*, *Dnmt3b* and *Dnmt3l*), methyl binding domain proteins (*Mecp2*, *Mbd2* and *Mbd3*) and histone deacetylases (*Hdac1* and *Hdac2*). Our results indicate that sub-chronic exposure of mice to SHS at a non-tumorigenic dose is insufficient to induce statistically significant changes in the transcription of key epigenetic modifiers.

2. Material and methods

2.1. Animal care and maintenance

Animals were bred and maintained in accordance with the recommendations of the National Institutes of Health provided in the Guide for the Care and Use of Laboratory Animals. The study was approved by the Institutional Animal Care and Use Committee (IACUC). All mice were kept in polypropylene cages in groups of 2–3 animals per cage, and housed in an air-conditioned animal

room with ambient temperature of $21 \pm 1^\circ\text{C}$ and relative humidity of 55% with 12-h light/dark cycle. Throughout all experiments, including the exposure phase and recovery period, the mice had access to food (PicoLab Rodent Diet 20, PMI Nutrition International, LLC., Brentwood, MO) and water *ad libitum*.

2.2. SHS exposure

The protocol used for SHS treatment of mice has been previously described in Refs. [9,12]. The breeding colony of mice used in the present study as well as in our previous reports [9,12] was originally obtained from Stratagene (Stratagene, La Jolla, CA). Stratagene was later acquired by Agilent Technologies Inc. (Agilent Technologies Inc., Santa Clara, CA). Briefly, male adult mice (6–8 weeks old) on a C57BL/6 genetic background were divided into two treatment groups ($n=5$ per group), including (I) four months exposure: T^4 and (II) four months exposure + seven months recovery in clean air: T^{4+7} . In our previously published studies, we have confirmed that this treatment protocol is well tolerated by mice, and can efficiently induce DNA damage and mutation as well as cause deregulation of gene expression [9,10,12,39]. We have also verified that short-term and long-term effects of SHS on the transcriptome can be established in this mouse model after a 4-month SHS exposure period and following seven months recovery in clean air, respectively [12]. SHS exposure was performed by burning 3R4F Reference Kentucky cigarettes (0.73 mg nicotine per cigarette, purchased from the Tobacco Research Institute, University of Kentucky, Lexington, KY) using a custom-made smoking machine (model TE-10, Teague Enterprises, Davis, CA) as previously described [9,12]. The TE-10 smoking machine was programmed to generate a mixture of sidestream smoke (89%) and mainstream smoke (11%), which is conventionally used to mimic SHS for experimental purposes [10,40].

All mice underwent an acclimatization period during which they were gradually exposed to incremental doses of SHS [9,12]. Following the acclimatization period, the animals were maintained on a SHS exposure regimen, which consisted of whole body exposure to SHS for 5 h per day, 5 days per week, for a duration of four months. Control mice were handled similarly to SHS-exposed animals, and underwent mock-exposure to filtered high-efficiency particulate-air (HEPA). At the end of SHS/mock-exposure and following the recovery period, the mice were euthanized by CO_2 asphyxiation. Lungs were harvested, snap-frozen in liquid nitrogen, and kept at -80°C until further analysis.

2.3. Quantitative reverse-transcription polymerase chain reaction

Standard quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was used to measure the expression level of major DNA methyltransferases, including *Dnmt1*, *Dnmt3a*, *Dnmt3b*, and *Dnmt3l*; methyl-binding domain proteins, including *Mecp2*, *Mbd2*, *Mbd3*; and histone deacetylases, including *Hdac1* and *Hdac2* [41,42]. Total RNA was extracted from the lungs of experimental and control mice as previously described [12]. DNase-treated RNA (0.5 μg) from T^4 and T^{4+7} mice was reverse transcribed into complementary DNA (cDNA) using SuperScript[®] VILO[™] cDNA Synthesis kit (Invitrogen). The expression level of target genes was determined by qRT-PCR using the TaKaRa SYBR[®] Premix Ex Taq[™] II (Tli RNaseH Plus) (Clontech Laboratories, Inc., Mountain View, CA, USA) and the CFX96 Touch[™] Real-Time PCR detection system (Bio-Rad). All experiments were performed in triplicate and fold changes were determined using the $2^{-\Delta\Delta\text{Ct}}$ method as previously described [41,42]. Data were normalized using the endogenous housekeeping gene, *Gapdh*, as reference. The primer sets used for qRT-PCR are available upon request.

Fig. 1. Expression of *Dnmt1*, *Dnmt3a*, *Dnmt3b* and *Dnmt3l* in SHS exposed mice versus control. Total RNA was extracted from the lungs of mice exposed to SHS for four months, immediately after discontinuation of exposure (T₄) and following 7-month recovery in clean air (T₄+7). The transcription level of genes encoding major DNMTs was examined by qRT-PCR using the $2^{-\Delta\Delta C_t}$ method [41]. Bars represent the mean normalized expression ($\pm$ SD) of triplicate samples in SHS-exposed mice and age-matched controls. Data were normalized using the endogenous housekeeping gene, *Gapdh*, as reference and controls as calibrators. Marginal differences in transcription levels between SHS-exposed and control mice were not statistically significant (Fisher's exact test).

3. Results and discussion

Exposure to SHS is a major risk factor for lung cancer in non-smokers [7]. However, the underlying molecular mechanism(s) of SHS-carcinogenicity is far from well-understood [7]. Recently, we have shown DNA damage-derived mutagenicity of SHS [9,10], and epigenetic deregulation of gene expression by a chemical constituent of SHS (i.e., benzo[a]pyrene) [11] in mice *in vivo*. The objective of this study was to determine whether SHS can indeed produce cancer-relevant changes in the epigenetic machinery in the same model system. Because aberrant DNA methylation and conformational changes in chromatin through post-translational modification of histones are the best-established mechanisms of carcinogenesis [17,43,44], we therefore investigated whether exposure to SHS can modulate the expression of key epigenetic regulators responsible for the establishment and/or maintenance of DNA methylation and histone modification patterns. We note that despite interspecies differences, the modulation of gene expres-

sion by cigarette smoke is mostly similar between humans and mice [45]. In addition, there is striking pathobiological resemblance between mouse and human lung cancer [46]. This validates the utility of mouse models for studying smoke-related carcinogenesis in humans [45].

Using genome-wide gene expression microarray analysis (Affymetrix Inc., Santa Clara, CA), we have previously characterized the lung transcriptome of mice exposed to sub-chronic doses of SHS [12]. Whereas we found a strong correlation between SHS exposure and aberrant gene expression (both reversible and irreversible) in cancer-related functional networks, we observed very subtle differences in the transcription of epigenetic modifiers between SHS-exposed mice and controls [12]. However, the microarray technology is known to suffer from inadequate sensitivity for detection of low-abundance transcripts and ratio compression that result in consistent underestimation of mRNA expression level ratios [47]. To circumvent this limitation of the microarray analysis, we herein used the 'gold standard' of gene expression analysis, i.e., quanti-

Fig. 2. Expression of *Mbd2*, *Mbd3*, and *Mecp2* in SHS exposed mice versus control. The transcription level of genes encoding major MBDs was examined in T⁴ and T⁴⁺⁷ mice by qRT-PCR using the $2^{-\Delta\Delta Ct}$ method [41]. Bars represent the mean normalized expression ($\pm$ SD) of triplicate samples in SHS-exposed mice and age-matched controls. Data were normalized using the endogenous housekeeping gene, *Gapdh*, as reference and controls as calibrators. Marginal differences in transcription levels between SHS-exposed and control mice were not statistically significant (Fisher's exact test).

tative real-time RT-PCR [48], to precisely measure the expression level of key epigenetic modifiers in the lungs of mice exposed to SHS using the same protocol as used in our previous report [12].

In the present study, we have exposed mice to a mutagenic, yet, non-tumorigenic dose of SHS for 5 h/day, 5 days/week for 4 months in exposure chambers of a microprocessor-controlled smoking machine. Subsequently, we have analyzed the pulmonary RNA of the SHS-exposed mice, immediately after termination of exposure (i.e., T⁴) and following seven months recovery in clean air (i.e., T⁴⁺⁷) to find the short-term and long-term effects, respectively, of SHS. Quantitative real-time RT-PCR was used to accurately quantify the mRNA levels of major DNA methyltransferases (*DNMTs*), methyl-CpG binding domain proteins (*MBDs*), and histone deacetylases (*HDACs*) in the lungs of SHS-exposed mice versus controls. Under the experimental conditions used in this study, we found no statistically significant differences in the transcription of *Dnmt1*, *Dnmt3a*, *Dnmt3b* and *Dnmt3l* genes between SHS-exposed mice and their age-matched controls (see, Fig. 1). Modest differences in gene expression were observed in T⁴⁺⁷ mice, with a 33–35% increase in *de novo* methyltransferases *Dnmt3a* and *Dnmt3b*, as compared to control. In T⁴⁺⁷ mice, relative transcription of *Mbd2* and *Mecp2* also increased to 35% and 30% respectively, while *Mbd3* levels remained

essentially unaffected (see, Fig. 2). These modest changes in the expression of major enzymes regulating CpG methylation patterns are consistent with our previous observations in which we found comparable patterns of DNA methylation between SHS-exposed mice and controls [39].

Earlier reports have demonstrated that cigarette smoke causes hyperacetylation of histones and decreased histone deacetylase activity in the lungs of smokers and patients with chronic obstructive pulmonary disease (COPD), as well as in the lungs of rodents exposed to cigarette smoke [49,50]. Thus, we examined the expression levels of two main HDACs, including *Hdac1* and *Hdac2*. Our qRT-PCR analysis on the pulmonary RNA of SHS-exposed mice showed that *Hdac1* and *Hdac2* transcripts decreased only slightly in T⁴ mice (up to 26%), while returning to baseline levels in T⁴⁺⁷ mice (see, Fig. 3).

Recently, we and others have analyzed the transcriptional status of *DNMTs*, *MBDs*, and *HDACs* in relation to ectopic DNA methylation during multi-step chemically induced carcinogenesis in animal models [11,51–53]. *In vivo* treatment of mice with potent carcinogens, including urethane, ethylnitrosourea (ENU), diethylstilbestrol (DES), and benzo[a]pyrene (B[a]P), induced dynamic changes in the expression of major epigenetic regulators, includ-

Fig. 3. Expression of *Hdac1* and *Hdac2* in SHS exposed mice versus control. The transcription level of genes encoding Class I HDACs was examined in T⁴ and T⁴⁺⁷ mice by qRT-PCR using the $2^{-\Delta\Delta Ct}$ method [41]. Bars represent the mean normalized expression ($\pm$ SD) of triplicate samples in SHS-exposed mice and age-matched controls. Data were normalized using the endogenous housekeeping gene, *Gapdh*, as reference and controls as calibrators. Marginal differences in transcription levels between SHS-exposed and control mice were not statistically significant (Fisher's exact test).

ing *Dnmt1*, *Dnmt3a*, *Dnmt3b*, *Mbd1*, *Mbd2*, *Mecp2*, *Hdac1* and *Hdac2* [11,51–53]. Deregulation of these epigenetic modifiers was associated with aberrant promoter CpG methylation of selected target genes [51–53] or found widespread in the genome [11]. Of importance, differences in DNA methylation patterns between carcinogen-treated animals and controls were readily detectable in apparently normal mice long before neoplastic lesion formation [11]. Unlike in the above reports, we have herein used SHS, which is a known weak mutagen and carcinogen [7,54,55]. To be consistent with our previous genetic [9,10], epigenetic [39], and transcriptomic [12] studies on SHS, we have also administered a mutagenic but non-tumorigenic dose of SHS since the focus of all our studies is on early biological effects of carcinogens. Comparing the findings of the present study with those of the above reports [11,51–53], one may ascribe the marginal changes in the expression levels of key epigenetic modifiers in our SHS-exposed mice, as opposed to those found in mice treated with powerful mutagens/carcinogens, to differences in test compounds and/or doses administered. Given the weak mutagenicity of SHS, it is also likely that this chemical is unable to sufficiently trigger active cell proliferation, a pre-requisite for establishment of epigenetic marks [27].

In addition to DNMTs, MBDs and HDACs, several other epigenetic regulators are emerging as key drivers, readers, editors or erasers of the epigenome [18–21]. Thus, one cannot rule out the possibility that SHS may modulate alternative epigenetic modifiers not analyzed in the present study. Potential candidates might include genes involved in miRNA regulation, chromatin remodeling, or other histone modifying enzymes [20]. Of relevance, our comprehensive analysis of the transcriptome in SHS-exposed mice indicated that several deregulated genes encode proteins that, alone or in combination with other remodeling factors, are involved in the deposition/reading of histone modifications, including ARID4B, KAT2B, and CHD4 [12]. Lastly, it is plausible that SHS may predominantly induce genotoxic effects, particularly at non-tumorigenic doses, whereas epigenetic effects may only be secondary and manifest *en route* to tumor formation.

In conclusion, we found no statistically significant changes in the expression of key epigenetic modifiers in the lungs of SHS-exposed mice as compared to age-matched controls (see, Figs. 1–3).

These findings are in agreement with those of our recent study in which we demonstrated comparable patterns of DNA methylation between SHS-exposed mice and controls [39]. In addition, the highly accurate single-gene RT-PCR analysis performed in this study reconfirms our previous genome-wide gene expression microarray analysis in which we showed fairly small changes in the transcription of epigenetic regulators in SHS-exposed mice [12]. Whether mutagenic SHS can cause genetic alterations in other master epigenetic regulators not analyzed in the present study and whether such alterations may result in reshaping of the epigenome in the lungs of nonsmokers is currently unknown and requires a thorough follow-up investigation.

Conflict of interest

All the authors declare no conflict of interest.

Acknowledgments

All authors have directly participated in the planning, execution, and analysis of this study. They have read and approved the final version submitted. They had full access to all the data in the study, and had final responsibility for the decision to submit for publication. Work of the authors was supported by a grant from the American Cancer Society (RSG-11-083-01-CNE) to A.B. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit for publication.

References

- [1] International Agency for Research on Cancer (IARC), Tobacco Smoke and Involuntary Smoking. World Health Organization (WHO), International Agency for Research on Cancer, Lyon, France, 2004, pp. 1191–1413.
- [2] The US. Surgeon General. The health consequences of involuntary exposure to tobacco smoke: A report of the surgeon general. 2006, 12–136.
- [3] M. Oberg, M.S. Jaakkola, A. Woodward, A. Peruga, A. Pruss-Ustun, Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries, *Lancet* 377 (2011) 139–146.
- [4] U.S. The Surgeon General, The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center

- for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health., Atlanta, GA, 2014.
- [5] M.J. Thun, S.J. Henley, D. Burns, A. Jemal, T.G. Shanks, E.E. Calle, Lung cancer death rates in lifelong nonsmokers, *J. Natl. Cancer Inst.* 98 (2006) 691–699.
- [6] S. Sun, J.H. Schiller, A.F. Gazdar, Lung cancer in never smokers—a different disease, *Nat. Rev. Cancer* 7 (2007) 778–790.
- [7] A. Besaratinia, G.P. Pfeifer, Second-hand smoke and human lung cancer, *Lancet Oncol.* 9 (2008) 657–666.
- [8] M. Sato, D.S. Shames, A.F. Gazdar, J.D. Minna, A translational view of the molecular pathogenesis of lung cancer, *J. Thorac. Oncol.* 2 (2007) 327–343.
- [9] S.I. Kim, V.M. Arlt, J.I. Yoon, K.J. Cole, G.P. Pfeifer, D.H. Phillips, A. Besaratinia, Whole body exposure of mice to secondhand smoke induces dose-dependent and persistent promutagenic DNA adducts in the lung, *Mutat. Res.* 716 (2011) 92–98.
- [10] S.I. Kim, J.I. Yoon, S. Tommasi, A. Besaratinia, New experimental data linking secondhand smoke exposure to lung cancer in nonsmokers, *FASEB J.* 26 (2012) 1845–1854.
- [11] S. Tommasi, A. Zheng, J.I. Yoon, A. Besaratinia, Epigenetic targeting of the Nanog pathway and signaling networks during chemical carcinogenesis, *Carcinogenesis* 35 (2014) 1726–1736.
- [12] S. Tommasi, A. Zheng, A. Besaratinia, Exposure of mice to secondhand smoke elicits both transient and long-lasting transcriptional changes in cancer-related functional networks, *Int. J. Cancer* 136 (2015) 2253–2263.
- [13] K.W. Lee, Z. Pausova, Cigarette smoking and DNA methylation, *Front. Genet.* 4 (2013) 2013.
- [14] I. Rhee, K.E. Bachman, B.H. Park, K.W. Jair, R.W. Yen, K.E. Schuebel, H. Cui, A.P. Feinberg, C. Lengauer, K.W. Kinzler, S.B. Baylin, B. Vogelstein, DNMT1 and DNMT3b cooperate to silence genes in human cancer cells, *Nature* 416 (2002) 552–556.
- [15] D. Gius, H. Cui, C.M. Bradbury, J. Cook, D.K. Smart, S. Zhao, L. Young, S.A. Brandenburg, Y. Hu, K.S. Bisht, A.S. Ho, D. Mattson, L. Sun, P.J. Munson, E.Y. Chuang, J.B. Mitchell, A.P. Feinberg, Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach, *Cancer Cell* 6 (2004) 361–371.
- [16] F.V. Jacinto, E. Ballestar, M. Esteller, Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation, *Oncogene* 28 (2009) 4212–4224.
- [17] M. Rodriguez-Paredes, M. Esteller, Cancer epigenetics reaches mainstream oncology, *Nat. Med.* 17 (2011) 330–339.
- [18] J.S. You, P.A. Jones, Cancer genetics and epigenetics: two sides of the same coin? *Cancer Cell* 22 (2012) 9–20.
- [19] H. Shen, P.W. Laird, Interplay between the cancer genome and epigenome, *Cell* 153 (2013) 38–55.
- [20] C. Plass, S.M. Pfister, A.M. Lindroth, O. Bogatyrova, R. Claus, P. Lichter, Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer, *Nat. Rev. Genet.* 14 (2013) 765–780.
- [21] Z. Yang, A. Jones, M. Widschwendter, A.E. Teschendorff, An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer, *Genome Biol.* 1640 (1) (2015).
- [22] H. Cedar, Y. Bergman, D. N. A. Linking methylation and histone modification: patterns and paradigms, *Nat. Rev. Genet.* 10 (2009) 295–304.
- [23] B. Jin, Y. Li, K.D. Robertson, DNA methylation: superior or subordinate in the epigenetic hierarchy? *Genes. Cancer* 2 (2011) 607–617.
- [24] N.R. Rose, R.J. Klose, Understanding the relationship between DNA methylation and histone lysine methylation, *Biochim. Biophys. Acta* 1839 (2014) 1362–1372.
- [25] P.A. Jones, G. Liang, Rethinking how DNA methylation patterns are maintained, *Nat. Rev. Genet.* 10 (2009) 805–811.
- [26] D. Subramaniam, R. Thombre, A. Dhar, S. Anant, DNA methyltransferases: a novel target for prevention and therapy, *Front. Oncol.* 4 (2014) 80.
- [27] A.V. Probst, E. Dunleavy, G. Almouzni, Epigenetic inheritance during the cell cycle, *Nat. Rev. Mol. Cell Biol.* 10 (2009) 192–206.
- [28] M.S. Karet, Z.M. Botello, J.J. Ennis, C. Chou, F. Chedin, Reconstitution and mechanism of the stimulation of de novo methylation by human DNMT3L, *J. Biol. Chem.* 281 (2006) 25893–25902.
- [29] B. Hendrich, A. Bird, Identification and characterization of a family of mammalian methyl-CpG binding proteins, *Mol. Cell Biol.* 18 (1998) 6538–6547.
- [30] Q. Du, P.L. Luu, C. Stirzaker, S.J. Clark, Methyl-CpG-binding domain proteins: readers of the epigenome, *Epigenomics* (2015) 1–23.
- [31] B. Barneda-Zahonero, M. Parra, Histone deacetylases and cancer, *Mol. Oncol.* 6 (2012) 579–589.
- [32] K.J. Falkenberg, R.W. Johnstone, Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders, *Nat. Rev. Drug Discov.* 13 (2014) 673–691.
- [33] L. Lopez-Serra, M. Esteller, Proteins that bind methylated DNA and human cancer: reading the wrong words, *Br. J. Cancer* 98 (2008) 1881–1885.
- [34] S. Roperio, M. Esteller, The role of histone deacetylases (HDACs) in human cancer, *Mol. Oncol.* 1 (2007) 19–25.
- [35] Y. Minamiya, T. Ono, H. Saito, N. Takahashi, M. Ito, M. Mitsui, S. Motoyama, J. Ogawa, Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung, *Lung Cancer* 74 (2011) 300–304.
- [36] H. Sasaki, S. Moriyama, Y. Nakashima, Y. Kobayashi, M. Kiriyama, I. Fukai, Y. Yamakawa, Y. Fujii, Histone deacetylase 1 mRNA expression in lung cancer, *Lung Cancer* 46 (2004) 171–178.
- [37] V.K. Cortessini, D.C. Thomas, A.J. Levine, C.V. Breton, T.M. Mack, K.D. Siegmund, R.W. Haile, P.W. Laird, Environmental epigenetics: prospects for studying epigenetic mediation of exposure-response relationships, *Hum. Genet.* 131 (2012) 1565–1589.
- [38] Z. Herceg, T. Vaissiere, Epigenetic mechanisms and cancer: an interface between the environment and the genome, *Epigenetics* 6 (2011) 804–819.
- [39] S. Tommasi, A. Zheng, J.I. Yoon, A.X. Li, X. Wu, A. Besaratinia, Whole DNA methylome profiling in mice exposed to secondhand smoke, *Epigenetics* 7 (2012) 1302–1314.
- [40] F. D'Agostini, A. Izzotti, R. Balansky, N. Zanesi, C.M. Croce, S. De Flora, Early loss of Flit in the respiratory tract of rodents exposed to environmental cigarette smoke, *Cancer Res.* 66 (2006) 3936–3941.
- [41] K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-(Delta Delta C(T))} Method, *Methods* 25 (2001) 402–408.
- [42] S. Tommasi, A. Zheng, A. Weninger, S.E. Bates, X.A. Li, X. Wu, M. Hollstein, A. Besaratinia, Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization, *Nucleic Acids Res.* 41 (2013) 182–195.
- [43] A. Portela, M. Esteller, Epigenetic modifications and human disease, *Nat. Biotechnol.* 28 (2010) 1057–1068.
- [44] S.B. Baylin, P.A. Jones, A decade of exploring the cancer epigenome—biological and translational implications, *Nat. Rev. Cancer* 11 (2011) 726–734.
- [45] M.C. Morissette, M. Lamontagne, J.C. Berube, G. Gaschler, A. Williams, C. Yauk, C. Couture, M. Laviolette, J.C. Hogg, W. Timens, S. Halappanavar, M.R. Stampfli, Y. Bosse, Impact of cigarette smoke on the human and mouse lungs: a gene-expression comparison study, *PLoS One* 9 (2014) e92498.
- [46] R. Meuwissen, A. Berns, Mouse models for human lung cancer, *Genes. Dev.* 19 (2005) 643–664.
- [47] S. Draghici, P. Khatri, A.C. Eklund, Z. Szallasi, Reliability and reproducibility issues in DNA microarray measurements, *Trends Genet.* 22 (2006) 101–109.
- [48] S. Mocellin, C.R. Rossi, P. Pilati, D. Nitti, F.M. Marincola, Quantitative real-time PCR: a powerful ally in cancer research, *Trends Mol. Med.* 9 (2003) 189–195.
- [49] P.J. Barnes, I.M. Adcock, K. Ito, Histone acetylation and deacetylation: importance in inflammatory lung diseases, *Eur. Respir. J.* 25 (2005) 552–563.
- [50] I.K. Sundar, M.Z. Nevid, A.E. Friedman, I. Rahman, Cigarette smoke induces distinct histone modifications in lung cells: implications for the pathogenesis of COPD and lung cancer, *J. Proteome Res.* 13 (2014) 982–996.
- [51] M. Pandey, K.P. Gupta, Epigenetics, an early event in the modulation of gene expression by inositol hexaphosphate in ethylnitrosourea exposed mouse lungs, *Nutr. Cancer* 63 (2011) 89–99.
- [52] Y. Li, K.J. Hamilton, A.Y. Lai, K.A. Burns, L. Li, P.A. Wade, K.S. Korach, Diethylstilbestrol (DES)-stimulated hormonal toxicity is mediated by ERalpha alteration of target gene methylation patterns and epigenetic modifiers (DNMT3A, MBD2, and HDAC2) in the mouse seminal vesicle, *Environ. Health Perspect.* 122 (2014) 262–268.
- [53] M. Pandey, S. Sahay, P. Tiwari, D.S. Upadhyay, S. Sultana, K.P. Gupta, Involvement of EZH2, SUV39H1, G9a and associated molecules in pathogenesis of urethane induced mouse lung tumors: potential targets for cancer control, *Toxicol. Appl. Pharmacol.* 280 (2014) 296–304.
- [54] S.S. Hecht, Tobacco carcinogens, their biomarkers and tobacco-induced cancer, *Nat. Rev. Cancer* 3 (2003) 733–744.
- [55] D.M. DeMarini, Genotoxicity of tobacco smoke and tobacco smoke condensate: a review, *Mutat. Res.* 567 (2004) 447–474.